BCL2 and small cell lung carcinoma: Combining venetoclax with other therapies has yielded even stronger antitumor effects than venetoclax alone in laboratory studies, suggesting that BCL-2 inhibition may be a valuable addition to combination treatment strategies for SCLC [141].